Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 6/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185372 | 0.90 | PTGDR2 (0.44) | PTGDR2 | |
| SCHEMBL10185151 | 0.90 | CCR3 (0.50) | CCR3HPGDPOLBHTTHRH1 | |
| SCHEMBL10185387 | 0.89 | CCR3 (0.43) | CCR3HRH1PTGDR2NPC1RAB9A | |
| SCHEMBL10185105 | 0.89 | CCR3 (0.49) | CCR3HPGDPOLBHTTHRH1 | |
| SCHEMBL10184913 | 0.88 | CCR3 (0.46) | CCR3HPGDPOLBHTTHRH1 | |
| SCHEMBL10184386 | 0.87 | CCR3 (0.42) | CCR3HPGDPTGDR2NPC1RAB9A | |
| SCHEMBL10185132 | 0.87 | HPGD (0.50) | CCR3HPGDPOLBHTTUTS2R | |
| SCHEMBL10184957 | 0.87 | DGAT1 (0.45) | RAB9A | |
| SCHEMBL10185228 | 0.86 | HRH3 (0.40) | CCR3PTGDR2 | |
| SCHEMBL10186432 | 0.85 | DGAT1 (0.43) | CCR3PTGDR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | CCR3 4296/4885HPGD 3492/4885POLB 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.